Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience

Briot, Karine; Ravaud, Philippe; Dargent-Molina, Patricia; Zylberman, Marcelo; Liu-Leage, Soyi; Roux, Christian

doi:10.1007/s00198-008-0698-8

Cited by 53 publications

(36 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Persistence data were particularly high (especially for daily drug treatment) as well as satisfaction with the program. These results were in line with similar programs for teriparatide conducted in France and the UK 9,10 . However, when broadening this issue of adherence to osteoporosis drugs to all available studies, the efficacy of patient education is much more controversial.…”

Section: I a L D I S T R I B U T I O N U N A U T H O R I Z E D U S supporting

confidence: 90%

The need for (cost)-effective interventions to enhance adherence with osteoporosis medications

Hiligsmann

Boonen

2013

Current Medical Research and Opinion

View full text Add to dashboard Cite

Section: I a L D I S T R I B U T I O N U N A U T H O R I Z E D U S supporting

confidence: 90%

The need for (cost)-effective interventions to enhance adherence with osteoporosis medications

Hiligsmann

Boonen

2013

Current Medical Research and Opinion

View full text Add to dashboard Cite

“…After first visit when therapy was prescribed, all our patients were met or contacted after 1 and 3 months (to control biochemical serum parameters, including potential calcium fluctuation) and visited again after six and 12 months to accomplish to the National health care prescription protocol. Training on self-administered subcutaneous injection (patients and/or their relatives), motivation instilled in the patients, subsequent visits to the first meeting set, possibility of contact by telephone (for potential presence of any problems or side effects), monitoring of blood test during the first months, when is higher the risk of treatment dropout, were all likely reasons which justify the high persistence and adherence to Teriparatide in our study as compared to others evaluating the same molecule (35)(36). Adverse events were few and modest; the self-administered subcutaneous injection of TPTD resulted easy for patients.…”

Section: Discussionmentioning

confidence: 75%

“…In particular the adherence to TPTD during the first semester treatment has allowed patients to obtain improvement of quality of life, and a strong stimulus for TPTD treatment persistence and adherence. Other studies have been performed in different countries (34)(35)(36)(37)(38) to examine persistence and adherence to the same treatment have found high persistence to the therapy but with lower rate (81%) after 18 months (35) while others have published data only at 12 months (37). A limitation of our study could be found in the fact that our patients suffered from severe osteoporosis and have previously sustained several fragility fractures, which had significantly impaired the quality of life and undoubtedly accentuated their awareness of the seriousness of the disease and willingness to continue the pharmacological treatment.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of persistence and adherence to teriparatide treatment in patients affected by severe osteoporosis (PATT): a multicenter observational real life study

Migliaccio

Resmini

Buffa³

et al. 2013

CCMBM

View full text Add to dashboard Cite

SummaryIntroduction. Osteoporosis is a chronic condition leading to an increased risk of developing fractures, with high morbidity and mortality in aging population. Efficacy of anti-osteoporotic treatment is based on drug potency but also on compliance and persistence to treatment regimen, which is very low, as already described for other diseases. Teriparatide (TPTD) is the first anabolic agent developed for the treatment of osteoporosis.

show abstract

“…(90) Similar results were seen in a French study looking at persistence in postmenopausal patients enrolled in an education and follow-up program and found that 81.5% were still on treatment at 15 months. (91) Recently, Black and colleagues (92) have shown that those who comply with therapy of PTH show better densitometric results.…”

Section: Safety In Hypoparathyroidism Trialsmentioning

confidence: 99%

Safety of osteoanabolic therapy: A decade of experience

Capriani

Irani

Bilezikian

2012

Journal of Bone and Mineral Research

131

View full text Add to dashboard Cite

IntroductionO steoporosis is a prevalent disease that affects more than 10 million Americans. The lifetime risk of an osteoporosisrelated fracture is 50% for Caucasian women and 25% for men. Hip fractures carry a 10% to 20% increase in mortality rate within the first year after fracture. (1) The burden of the hip and other fractures can result in chronic pain, disability and other indices of reduced quality of life.Amidst these sobering statistics is the welcome advent over the past two decades of effective pharmacological therapies that reduce fracture risk. The therapies approved for the management of osteoporosis include bisphosphonates, raloxifene (a selective estrogen-receptor modulator), calcitonin, denosumab, strontium ranelate, and parathyroid hormone and PTH(1-84)]. The fulllength PTH molecule and its foreshortened amino-terminal fragment (teriparatide) are currently the only osteoanabolic agents approved for use. PTH(1-84) is not available in the United States. In November, 2002, teriparatide was approved by the U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis and, later, in men. The approval came with restrictions in duration of therapy (18-24 months) and was limited to individuals with advanced osteoporosis at high risk for fracture. Reasons for these limitations relate, at least in part, to the unexpected occurrence of osteosarcoma and other bone neoplasms in Fischer 344 rat toxicity studies. In fact, the pivotal phase 3 trial of teriparatide was suspended when these rat toxicity data became available. The effects on rats was doseand duration-dependent, with rats being treated for approximately 80% of their lifetime and at doses three to 58 times the currently approved human dose. (2) Similar toxicity was seen for PTH(1-84) (3) Given the clear-cut efficacy data when the results of the abbreviated clinical trial results for teriparatide were analyzed, the FDA and equivalent other agencies in Europe and elsewhere granted approval of teriparatide with the stipulations that it should be used for no longer than 2 years. In the United States, the drug carries a ''black box warning'' and contraindicates its use in patients with existing risk factors for osteosarcoma, including Paget's disease of bone, prior skeletal radiation, and children with open epiphyses.Teriparatide has now been used in the United States for 10 years. With a decade of experience, it is timely to review the efficacy and safety profile of this medication. PTH(1-84) will also be reviewed. This perspective will be limited to PTH formulations that are available for the treatment of osteoporosis; we will not be discussing other anabolic agents that are currently being studied but are not yet approved, such as the sclerostin antibody (http://clinicaltrials.gov/ct2/results?term ¼ sclerostin þ anti-þ antibody). PTH mechanisms of actionTeriparatide is an amino-terminal fragment of PTH that is biologically identical to the amino-terminal fragment of human PTH. This fragment contains all the classical bio...

show abstract

Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience

Abstract: Postmenopausal osteoporotic women treated by teriparatide and enrolled in an education and follow-up program have a high persistence rate.

Cited by 53 publications

References 19 publications

The need for (cost)-effective interventions to enhance adherence with osteoporosis medications

The need for (cost)-effective interventions to enhance adherence with osteoporosis medications

Evaluation of persistence and adherence to teriparatide treatment in patients affected by severe osteoporosis (PATT): a multicenter observational real life study

Safety of osteoanabolic therapy: A decade of experience

Contact Info

Product

Resources

About